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Background: Recombinant human growth hormone (rhGH) can increase the growth rate in growth hormone
deficient children (GHD). In this randomized clinical trial, we compared the efficacy and side effects of an Iranian
brand; Samtropin with Norditropin.
Methods: The GHD children were randomly treated either with standard dose of Samtropin or Norditropin rhGH
for one year. Upstanding height, height standard deviation score (HSDS), growth velocity (GV), serum levels of
insulin like growth factor-1 (IGF-1), and bone age (BA) were determined before and during one year treatment
concomitant side effects of treatment.
Results: We evaluated 22 subjects; 12 on Samtropin and, 10 on Norditropin. In each group, mean age was 12 yr
and 50% of them were male. The mean differences in height, HSDS, IGF-1 and BA by Norditropin before and after
12 months were 8.8 cm, 0.5, 49 ng/ml and 2.8 yr, respectively. These measures by Samtropin were 9.1 cm, 0.6,
133 ng/ml, and 1.7 yr, respectively without any significant difference. The mean of GV by Samtropin was 9.1 vs.
8.8 cm by Norditropin without significant difference. Since the efficacy of Samtropin was found to be similar to
Norditropin after 12 months; we switched to use only Samtropin for the next 12 months. The mean differences in
height, HSDS, GV and BA in 20 children between months 12 and 24 were 7.0 cm, 1.6, 2.1 cm/yr and 1.0 yr,
respectively (P < 0.001). We also found a non-significant decrease in IGF-1 levels. No side effects were observed.
Conclusions: We need to conduct a post marketing surveillance with a large sample size in order to confirm our
findings.
Trial registration: Registration code number in the Iranian Registry of Clinical Trials (IRCT): IRCT1138901181414N11.
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ChildrenIntroduction
Recombinant human growth hormone (rhGH) has been
established as an appropriate treatment to increase the
growth rate in children with growth hormone deficiency
(GHD), Turner syndrome (TS), Prader-Willi syndrome
(PWS), chronic renal failure (CRF), and being born small* Correspondence: emrc@tums.ac.ir
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article, unless otherwise stated.for gestational age (SGA) [1]. Considering the large
heterogeneity in diagnosis of GHD in children, its prev-
alence and incidence is largely varied in different countries
[2,3]. However, its appropriate treatment is important, be-
cause these children are at higher risk of social isolation
[4], anxiety and poor school performance [5], cardiovascu-
lar morbidity [6], type 2 diabetes mellitus and metabolic
syndrome [7,8].
It is shown that rhGH could improve the linear growth
partly through stimulation of the production of insulin
like growth factor-1 (IGF-1) [9]. IGF-1 has insulin likeed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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deling [9].
The rhGH is derived from recombinant DNA and is
produced by several pharmaceutical companies such as
Genentech, NOVO Nordisk, Serono, etc. [10]. All of
these products have equivalent therapeutic efficacy and
pharmacokinetic properties [11]. Since the cost of GH
therapy is substantial; it considers as an important issue
for medical resources allocation. Given the current treat-
ment costs in the United States, this correspondence to
more than 50,000 $ USD per inch (2.54 cm) gained in
adult height; which is a significant expense for any
health system [12]. To lower the cost, one solution
would be the production of rhGH by several pharma-
ceutical companies, especially domestic companies. Re-
cently, Samtropin rhGH has been produced by an
Iranian Pharmaceutical Company; Samen. However to
establish its efficacy and safety, we should compare it
with a Food and Drug Administration (FDA) approved
rhGH. The aim of the present study was to demonstrate
the safety and efficacy of Samtropin in comparison with
Norditropin; a product that is manufactured by NOVO
Nordisk Company to treat the linear growth failure in
pediatric GHD. By performing this study we may be able
to present the Samtropin rhGH as a less expensive drug
for treatment of GHD children.
Materials & methods
Study population
This parallel non-inferiority/equivalence randomized clin-
ical trial (RCT) study was carried out from August 2006
to April 2011 to compare the efficacy and side effects of
Iranian brand of rhGH; Samtropin (Samen Company)
to Norditropin (NOVO Nordisk Company) in pediatric
GHD. Before starting the study, informed consent was ob-
tained from all eligible children. GHD in children was
diagnosed by failure to reach serum GH levels ≥10 ng/ml
by clonidine GH-stimulation test] [13]. Inclusion criteria of
the study was defined as non-pubertal children who have
height standard deviation score (HSDS) < −3SD, or short
stature children who have concomitant level of IGF-1
below that of children of the same chronological age and
sex recorded for IGF-1 kit. Exclusion criteria were set as:
other causes of GHD such as hypothyroidism, celiac, any
acute or systemic infection diseases, seizure, HIV disorder,
any chronic systemic disorders such as diabetes mellitus
or CRF, TS, sleep apnea syndrome, active cancers, acute
phase of craniopharengioma or other contraindications of
GH replacement therapy, and concomitant use of
corticosteroid.
This study included two phases. In the first phase;
patients were divided in a random double blind man-
ner into two groups; intervention group who received
Samtropin and control group who received Norditropin.Both groups received the treatment over a period of
12 months, as a bed time subcutaneous injection at dose
of 0.04 mg (0.1 IU)/Kgw/day, with maximum dose of
4 IU/day. We used same form of rhGH (vial) with simi-
lar color and package with a lable. The main researcher
and patients were blinded to the interventions. The lable
was a code cleared only for the third adviser. All the en-
rolled children were visited by a physician every month
for the first 6 months, and then at 12th month after
starting treatment to assess response to rhGH treatment.
The assessed parameters were height, HSDS, growth
velocity (GV), weight standard deviation score (WSDS),
bone age (BA), and serum levels of IGF-1. GV was deter-
mined according to below formula:
GV ¼ height at the end of 12 months after treatment cmð Þ−initial height before treatment cmð Þ
chronogical age at the end of 12 months after treatment yearð Þ−initial chronogical age before treatment yearð Þ
Parents’ height was assessed before initiating the study
to predict the height potential of children (PHP). We
used the cross-sectional data provided by the National
Center for Health Statistics (NCHS) from the Centers
for Diseases Control (CDC) web site to estimate HSDS
and WSDS [14]. Pubertal status was assessed and scored
at each visit according to Marshall-Tunner staging [15].
Bone age was determined before and at the end of one
year treatment.
Safety of the treatment was assessed by monitoring the
adverse effects, measuring the body weight, performing
the laboratory tests, and fundoscopy. Adverse effects
were assessed in each visit according to a questionnaire
consisting these signs; headache, edema, arthralgia,
vomiting, hypoglycemia, genicomastia, lipoathrophia or
lipohyperthrophia or local reaction in injection site,
carpal tunnel syndrome, obesity, vertigo, seizure, recent
visual deficit and muscle cramp. Laboratory tests in-
cluded the routine hematology tests, blood chemistry,
glucose metabolism (fasting blood sugar), and thyroid
hormone; free thyroxin (FT4). Fundoscopy was per-
formed at the baseline for all the patients and during the
course of study forpatients who developed headache or
signs of intracranial hypertension.
At the end of first year, we analyzed the findings and
we found similarity in the therapeutic effects of these
two brands; height, HSDS, GV, BA and IGF-1. Based on
this finding, the second phase of the study was designed
to examine the Samtropin’s therapy impact on growth
parameters. To do this, Samtropin therapy was con-
tinued for the next 12 months for all the patients, and
height and HSDS were measured at 18th, and 24th
month of the study. Moreover, probable side effects and
puberty status were assessed at the above time points ac-
cording to the same criteria of the first phase. Bone age,
IGF-1, glucose metabolism and thyroid hormone level
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study.
The study was approved by ethical committee of Endo-
crinology and Metabolism Research Center (EMRC) of
Endocrinology and Metabolism Clinical Sciences Institute
of Tehran University of Medical Sciences (TUMS) and
registered in the Iranian Registry of Clinical Trials (IRCT)
as code number of IRCT1138901181414N11.
Laboratory methods
Fasting blood samples were obtained from all subjects to
evaluate below biochemical measures; CBC-diff, blood urea
nitrogen (BUN), creatinine (Cr), alkaline phosphates (Alkp),
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), fasting blood sugar (FBS), sodium (Na), potassium
(K), FT4, and IGF-1. FBS and BUN were measured by
enzymatic method, using Pars- Azmon kit/Iran. Cr was
measured by JAFFE method (Pars- Azmon kit/Iran). Alkp,
ALT, and AST were measured using photometer assay,
enzymatic method. Na and K were measured by flame
photometer Coring 480/US. CBC-diff was assessed by cell
counter ABACUS. FT4 was measured by ELISA method
using monobind kit/USA. IGF-1 was measured by RIA
method using Immunotech kit/Chekslovaki, ranging 76–
499 ng/ml for children aged more than 4 years.Figure 1 Flow diagram of the study.Statistical analysis
The normal distribution of data was evaluated by
Kolmogrov-Smirnov analytic test. After determining the
mean of variables, the student two-tailed t test was ap-
plied to compare the mean differences. Repeated mea-
sures were used to compare the trend of variables in
different times. SPSS software (version 16) was used to




From 45 initially evaluated subjects, after considering in-
clusion and exclusion criteria, 22 patients were eligible
to be enrolled in the study. Flow diagram of the study is
shown in Figure 1.
The baseline characteristics of 22 patients are summa-
rized in Table 1 (10 children in NOVO group as control
group, and 12 children in Samen group as intervention
group). The mean age in both groups was similar (12 yr).
In each group, 50% of the participants were male and most
of them were in non-pubertal status. There were no sig-
nificant differences in baseline characteristics of patients
between two groups. All the children except one, who was
undertreatment with levothyroxin, had normal FT4 levels.







Chorological age (yr) 11.73 ± 1.2 12.01 ± 1.72 NS
Male/ Female (n) 5/5 6/6 NS
Pubertal status Mixed (1 puberty) Mixed (2 puberty) NS
Height (cm) 129.41 ± 7.32 133.47 ± 9.91 NS
Weight (Kg) 27.40 ± 4.86 30.21 ± 7.39 NS
HSDS −3.39 ± 0.66 −2.89 ± 0.44 NS
WSDS −2.27 ± 0.92 −2.29 ± 1.27 NS
Bone age (yr) 8.71 ± 1.53 9.63 ± 2.26 NS
Maximum stimulated
GH (ng/ml)
6.1 ± 3.7 8.0 ± 6.6 NS
IGF-1 (ng/ml) 213 ± 123 304 ± 221 NS
FBS (mg/dl) 86.10 ± 13.07 94.08 ± 3.96 NS
Cr (mg/dl) 0.62 ± 0.10 0.66 ± 0.09 NS
BUN (mg/dl) 32.00 ± 16.90 20.17 ± 10.26 NS
ALKP (mg/dl) 495.60 ± 250.82 558.92 ± 204.02 NS
ALT (mg/dl) 19.10 ± 6.26 18.82 ± 6.94 NS
AST (mg/dl) 28.40 ± 4.17 29.00 ± 6.41 NS
Na (mg/dl) 139.22 ± 1.71 139.80 ± 2.53 NS
K (mg/dl) 4.15 ± 0.35 4.13 ± 0.37 NS
Legend: HSDS: Height Standard Deviation Score, WSDS: Weight Standard
Deviation Score, IGF-1: Insulin like growth factor-1, FBS: Fasting Blood Sugar,
Cr:creatinine, BUN: Blood Urea Nitrogen, ALKP: Alkaline Phosphates,
ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, Na: Sodium,
K: Potassium, NS: Non significant, yr: year, n: number.
Data are presented as mean ± SD according to paired T-Test.
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duced by Norditropin after 12 months of treatment were
8.8 cm, 0.5, and 49 ng/ml, respectively, while these mea-
sures by Samtropin were 9.1 cm, 0.6, and 133 ng/ml, re-
spectively. No significant difference was detected between
groups (Table 2). Figures 2, 3 and 4 show the trend of
change in height, HSDS and IGF-1 during 12 months
treatment with NOVO or Samen rhGH.
The mean of WSDS in NOVO group at baseline and





Height (cm) NOVO 128.8 ± 6.5 133.9 ± 5.8
Samen 132.8 ± 9.9 137.4 ± 9.8
HSDS NOVO −3.4 ± 0.7 −2.9 ± 0.7
Samen −2.9 ± 0.4 −2.5 ± 0.6
IGF-1(ng/ml) NOVO 481 ± 174 432 ± 210
Samen 391 ± 185 475 ± 274
Legend: HSDS: Height Standard Deviation Score, IGF-1: Insulin like growth factor-1,
*P ≤ 0.05 was considered statistically significant in Repeated measures Test.respectively, without statistically significant difference
within group (p = 0.20). These figures within Samen
group were −2.3 and −1.6, respectively (p = 0.009). There
was no significant difference in mean difference of
WSDS after 12 months rhGH therapy between groups
(p = 0.22). Mean of BA from a baseline value of 8.7 year
increased to 11.6 year at month 12 (P < 0.001) in NOVO
group and from 9.6 year to 11.3 year (p = 0.004) in
Samen group. The mean difference of BA after 1 year
treatment with Norditropin rhGH was 2.8 year and with
Samtropin rhGH was 1.7 (p = 0.11).
The mean of PHP for NOVO group was 159.3 cm and
its difference with the baseline height of this group was
30.4 cm (P < 0.001). This difference changed to 21.7 cm at
month 12 (P < 0.001). The mean of PHP in Samen group
was 162.1 cm and its difference with the baseline height of
this group was 29.3 cm (P < 0.001). The measure changed
to a mean of 20.2 cm at month 12 (P < 0.001). No re-
markable difference in mean difference height from PHP
after one year treatment between two groups was detected
(p = 0.74). The mean of GV induced by Samtropin rhGH
was similar to Norditropin; 9.1 vs. 8.8 cm, respectively
without significant difference.
Neither life-threatening adverse events nor significant
changes in biochemical tests were reported during the
study in both groups.
The second phase
Since the efficacy of Samtropin rhGH was similar to Nordi-
tropin after 12 months treatment; we switched to use only
Samtropin in all children for the next 12 months. Within
22 patients entered the second phase of the study, 20 chil-
dren completed this phase. In this phase, we considered
12th month as baseline and 24th month as the end of
study’s second phase. The mean of Height, HSDS and GV
at the 12th month of the study were 140.1 cm, −2.5 and 9.1
(Table 3). These figures changed to 147.1 cm, −0.9, and
7.0, respectively at the 24th month of the study (p < 0.001).
Figures 5, 6 and 7 demonstrate the trends of height,
HSDS and GV during 12 months treatment in the sec-







137.6 ± 6.1 <0.001* NS
141.9 ± 9.2 <0.001*
−2.9 ± 0.8 0.007* NS
−2.3 ± 0.4 0.011*
432 ± 199 NS NS
524 ± 263
NS:non significant.
Figure 2 Trend of height status in NOVO or Samen group in
the first phase of the study (12 months).
Figure 4 Trend of IGF-1 means in NOVO or Samen group in the
first phase of the study (12 months).
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phase was −1.8 ± 1.5 and 11.4 ± 1.9 yr, respectively, which
was improved significantly to 0.6 ± 1.3 and 12.4 ± 2.0 yr
(p < 0.001 and p < 0.05), respectively after 12 months of treat-
ment. A non-significant decrease (p = 0.26) in serum IGF-1
levels was detected between baseline (539 ± 268 ng/ml) and
month 24 of the study (429 ± 220 ng/ml). The mean dif-
ference in PHP between baseline and month 12 of the
study was 20.6. This figure declines to 13.6 cm (P < 0.001)
at month 24.
Similar to results reported in the first phase of the
study, in the second phase we found neither life-
threatening adverse events nor significant changes in la-
boratory data.Figure 3 Trend of HSDS in NOVO or Samen group in the first
phase of the study (12 months).Discussion
Auxological parameters
Height, HSDS, and GV are well established measures of
linear growth during rhGH treatment, particularly dur-
ing the usual pre-pubertal age [16,17]. In our study we
found an improvement in height, HSDS, and GV values
which could be assumed as the efficient growth response
of the children to Samtropin. Similar to other published
studies [18-20] for all these auxological parameters,
significant differences were observed between values of
baseline and month 12 of the study within NOVO or
Samen groups. However, no significant difference bet-
ween these two groups was observed. Moreover, this
treatment response was not affected by switching from
Norditropin to Samtropin in the second phase of the
study.
After one year treatment with Samtropin, height dif-
ference was 9.1 cm, a change that waseven more than
height gained by Norditropin treatment (8.8 cm). It is
generally accepted that an increase of at least 0.25 SD in
HSDS over the first year of treatment is a definitive evi-
dence of rhGH efficacy [16]. The increase in HSDS after
treatment with rhGH therapy in our study was 0.57 by
Samtropin and 0.52 by Norditropin without any signifi-
cant difference between them. When we considered the
two years treatment by rhGH in our patients regardless
of the brand employed, we found the significant change
in HSDS from −2.5 at baseline to −0.9, a figure that is in
agreement with other studies [21-23]. Root et al. [21] re-
ported that HSDS increased from a mean value of −3.4
to −1.5 after 4 years treatment with Omnitrope in 140
GHD children. Coste et al. [22] reported in French GHD
children a HSDS of −2.0 compared with a HSDS of −1.3
after 4 years of treatment with Omnitrope. These figures
Table 3 Comparison of growth responses to Samtropin rhGH during the second phase of the study
Variables Baseline (at 12th month) (mean ± SD) At 18th month (mean ± SD) At 24th month (mean ± SD) P-value of Trend
Height (cm) 140.1 ± 8.4 144.1 ± 8.0 147.1 ± 8.0 <0.001*
HSDS −2.5 ± 0.6 −2.1 ± 0.6 −0.9 ± 0.4 <0.001*
GV(cm/yr) 9.1 ± 1.5 3.9 ± 1.6 7.0 ± 1.9 <0.001*
Legend: HSDS: Height Standard Deviation Score, GV: growth velocity.
*P ≤ 0.05 was considered statistically significant in Repeated measures Test.
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ment with Omnitrope in British children [23].
The standard curves of height could be affected by the
pubertal growth spurt. On the other hand, in children
with delayed puberty the changes in HSDS can be masked
by using rhGH. Therefore, it seems that GV value may be
a more appropriate measure of rhGH response in such
children. Inboth our groups, the mean GV increased
equally (9.1 vs. 8.8 cm/year), after 12 months of treatment
with rhGH. The mean GV increased equally again in both
groups (2.1 cm/year) in the second phase of study. Similar
to findings of the other published studies [19,22,24,25] the
greatest acceleration in GV was occurred during the first
year of the rhGH treatment in our study.
Pharmacodynamic parameter
IGF-1 is defined as the preferred pharmacodynamic marker
for assessing theactivity of rhGH in similar medicinal pro-
ducts containing somatropin [26]. IGF-1 levels tend to be
low in GHD and rise in a dose-dependent manner in chil-
dren treated with rhGH [27]. Scire et al. [28] demonstrated




























Figure 5 Trend of height status in the second phase of the study (froabnormal elevation of IGF-1 in GHD children does not
occur. In our study, Samtropin similar to Norditropin stim-
ulated the synthesis of IGF-1 which was detected by signifi-
cant increase in IGF-1 serum level after 12 months of
treatment. The increase was more pronounced during the
first 6 month of treatment, the time period when the growth
of patients was observed to be most accelerated. The in-
crease in IGF-1 level from baseline to which achieved after
12 months treatment with Samtropin in our study was very
similar to other studies [18,29]. The mean level of IGF-1
was decreased non-significantly in the second phase of
study.
PHP and bone maturation
The PHP corresponds to the height that patient is ex-
pected to reach at the end of linear growth. In our study,
the mean difference of PHP and the height of children
after 1 year treatment with rhGH in NOVO group was
30.6 cm and for Samen group was 29.3 cm, without any
significant difference between groups. When we contin-
ued the rhGH therapy with Samtropin for the second
year, the mean difference between PHP and the heightime
24mo18mo

























Figure 6 Trend of HSDS status in the second phase of the study (from 12th month to 24th month).
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rhGH could be influenced by several factors such as dos-
ages of rhGH, degree of delay in growth and skeletal age
before initial treatment, and manipulation of puberty
[30]. Before starting treatment, we had 3 children who
were in pubertal stage; one child in NOVO group and 2
children in Samen group. The number of pubertal kids
increased to 11 subjects at the end of 2 years. This fact
could lead to variation in response to rhGH particularly






















Figure 7 Trend of GV in the second phase of the study (from 12th moAfter 1 year treatment with Samtropin the bone age of
our patients increased by 1.71 year, whilst this figure for
Norditropin was 2.85 year. Although the effect of Samtropin
on bone age was lower than the effect of Norditropin,
there was not any significant difference between treatment
groups. The effect of Samtropin on the bone age in the
second phase was equal to 1 year. The effect of Samtropin
on bone age for the second year was equal to the chrono-
logical age. This finding is important since itshows the
normal pace of bone maturation, and also illustrates thatime
24mo8mo
nth to 24th month).
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rhGH products including Omnitrope and Saizen [18,20].
Similar to our other findings, the most pronounced effect
of Samtropin was produced in the first year of treatment.
In the other word, the potential gain in height decreased
as the treatment period was increased.
Safety
Mean values of blood chemistry were within normal
ranges during study. Monitoring of free T4 and TSH is
recommended for detecting hypothyroidism which may
appear during rhGH therapy [31,32]. None of our studied
children developed low FT4 while were on rhGH therapy.
The rhGH therapy may induce carbohydrate intolerance
in children with compromised insulin secretion [33].
None of our children in two phases of the study developed
glucose intolerance asmeasured by FBS. This finding is in
agreement with Aman et al. [34] and Soliman et al. [35]
findings who demonstrated that rhGH therapy could not
produce any negative effect on FBS. Overall the safety
profile of our treatments was similar to findings of other
published studies [29,35] with no significant changes bet-
ween our groups. All of our safety assessment results were
in agreement with other studies that reviewed the short
and long term safety of rhGH therapy [36-38]. The most
frequent adverse effects reported by other products were
headache, eosinophilia, hypothyroidism and injection site
reactions [19]. Overall the side effects of rhGH therapy
are uncommon and reversible after discontinuation or
dose reduction of treatment [30].
Limitations of the study
We have to mention that our experiment has some limi-
tations. We did not measure the free IGF-1 or IGF bin-
ding protein-3 (IGFBP-3) as a carrier of IGF-1 in serum.
Serum level of IGF-1 reflects the 24-hour secretion of
GH. However, the general believe is that free IGF-1 is a
biologically active component of IGF-1 [29]. Further-
more, the free IGF-1 is controlled by IGFBP-3 [29]. Our
small sample size is another limitation. We understood
that we need to design a post marketing surveillance
with a larger sample size in order to confirm our fin-
dings, however the result of this study have implications
for clinical practice and health policy.
Conclusions
In conclusion, the clinical comparability between Nordi-
tropin and Samtropin demonstrated that Samtropinat a
dose of 0.04 mg/kg/day is effective to increase the linear
growth, safe and well tolerated both locally and syste-
mically within 12 months treatment of GHD children.
Although, the results of this study are supportive of the
long term (up to 2 years) benefits of Samtropin rhGH in
GHD children, interpretation of the finding should bedone with caution since the second phase of our study
was not a comparative, randomized trial. Considering that
only small number of our patients received Samtropin for
the full 2 years, the long term (2 years) treatment with
Samtropin was efficient and well tolerated.
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